Tetraspanins as therapeutic targets in hematological malignancy: A concise review

Frontiers in Physiology

Volumn 6, Issue MAR, 2015, Pages

  Beckwith, Kyle A ^a   Byrd, John C ^a   Muthusamy, Natarajan ^a  

^a OHIO STATE UNIVERSITY   (United States)

Author keywords

CD37; CD53; Tetraspanin; TSPAN

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; ANTINEOPLASTIC AGENT; BENDAMUSTINE; CD151 ANTIGEN; CD37 ANTIGEN; CD53 ANTIGEN; CD81 ANTIGEN; CD82 ANTIGEN; CD9 ANTIGEN; IDELALISIB; IMGN 529; MONOCLONAL ANTIBODY 37.1; OTLERTUZUMAB; RITUXIMAB; SMIP 016; TETRASPANIN; TETRASPANIN 32; TETRASPANIN 33; TETULOMAB TETRAXETAN LUTETIUM LU 177; UNCLASSIFIED DRUG;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; CANCER COMBINATION CHEMOTHERAPY; CHRONIC LYMPHATIC LEUKEMIA; DRUG CYTOTOXICITY; DRUG EFFECT; DRUG POTENTIATION; DRUG TARGETING; DRUG TOLERABILITY; HEMATOLOGIC MALIGNANCY; HUMAN; MONOTHERAPY; MULTIPLE MYELOMA; NEUTROPENIA; NONHODGKIN LYMPHOMA; NONHUMAN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE; REVIEW;

EID: 84926456125     PISSN: None     EISSN: 1664042X     Source Type: Journal    
DOI: 10.3389/fphys.2015.00091     Document Type: Review

References (115)

1. Amiot, M. (1990). Identification and analysis of cDNA clones encoding CD53. A pan-leukocyte antigen related to membrane transport proteins. J. Immunol . 145, 4322-4325.
2. Andre, M., Le Caer, J. P., Greco, C., Planchon, S., El Nemer, W., Boucheix, C., et al. (2006). Proteomic analysis of the tetraspanin web using LC-ESI-MS/MS and MALDI-FTICR-MS. Proteomics 6, 1437-1449. doi: 10.1002/pmic.200500180
3. Angelisová, P., Hilgert, I., and Horejsí, V. (1994). Association of four antigens of the tetraspans family (CD37, CD53, TAPA-1, and R2/C33) with MHC class II glycoproteins. Immunogenetics 39, 249-256. doi: 10.1007/BF00188787
4. Bandyopadhyay, S., Zhan, R., Chaudhuri, A., Watabe, M., Pai, S. K., Hirota, S., et al. (2006). Interaction of KAI1 on tumor cells with DARC on vascular endothelium leads to metastasis suppression. Nat. Med . 12, 933-938. doi: 10.1038/nm1444
5. Barreiro, O., Yanez-Mo, M., Sala-Valdes, M., Gutierrez-Lopez, M. D., Ovalle, S., Higginbottom, A., et al. (2005). Endothelial tetraspanin microdomains regulate leukocyte firm adhesion during extravasation. Blood 105, 2852-2861. doi: 10.1182/blood-2004-09-3606
6. Barrena, S., Almeida, J., Yunta, M., Lopez, A., Fernandez-Mosteirin, N., Giralt, M., et al. (2005). Aberrant expression of tetraspanin molecules in B-cell chronic lymphoproliferative disorders and its correlation with normal B-cell maturation. Leukemia 19, 1376-1383. doi: 10.1038/sj.leu.2403822
7. Beckmann, J., Scheitza, S., Wernet, P., Fischer, J. C., and Giebel, B. (2007). Asymmetric cell division within the human hematopoietic stem and progenitor cell compartment: identification of asymmetrically segregating proteins. Blood 109, 5494-5501. doi: 10.1182/blood-2006-11-055921
8. Beckwith, K. A., Frissora, F. W., Stefanovski, M. R., Towns, W. H., Cheney, C., Mo, X., et al. (2014). The CD37-targeted antibody-drug conjugate IMGN529 is highly active against human CLL and in a novel CD37 transgenic murine leukemia model. Leukemia 28, 1501-1510. doi: 10.1038/leu.2014.32
9. Bell, G. M., Seaman, W. E., Niemi, E. C., and Imboden, J. B. (1992). The OX-44 molecule couples to signaling pathways and is associated with CD2 on rat T lymphocytes and a natural killer cell line. J. Exp. Med . 175, 527-536. doi: 10.1084/jem.175.2.527
10. Berditchevski, F., Odintsova, E., Sawada, S., and Gilbert, E. (2002). Expression of the palmitoylation-deficient CD151 weakens the association of alpha 3 beta 1 integrin with the tetraspanin-enriched microdomains and affects integrin-dependent signaling. J. Biol. Chem . 277, 36991-37000. doi: 10.1074/jbc.M205265200
11. Berditchevski, F., Tolias, K. F., Wong, K., Carpenter, C. L., and Hemler, M. E. (1997). A novel link between integrins, transmembrane-4 superfamily proteins (CD63 and CD81), and phosphatidylinositol 4-kinase. J. Biol. Chem . 272, 2595-2598. doi: 10.1074/jbc.272.5.2595
12. Bos, S. D., Lakenberg, N., Van Der Breggen, R., Houwing-Duistermaat, J. J., Kloppenburg, M., De Craen, A. J., et al. (2010). A genome-wide linkage scan reveals CD53 as an important regulator of innate TNF-alpha levels. Eur. J. Hum. Genet . 18, 953-959. doi: 10.1038/ejhg.2010.52
13. Bosca, L., and Lazo, P. A. (1994). Induction of nitric oxide release by MRC OX-44 (anti-CD53) through a protein kinase C-dependent pathway in rat macrophages. J. Exp. Med . 179, 1119-1126. doi: 10.1084/jem.179.4.1119
14. Byrd, J. C., Murphy, T., Howard, R. S., Lucas, M. S., Goodrich, A., Park, K., et al. (2001). Rituximab using a thrice weekly dosing schedule in B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicity. J. Clin. Oncol . 19, 2153-2164.
15. Byrd, J. C., Pagel, J. M., Awan, F. T., Forero, A., Flinn, I. W., Deauna-Limayo, D. P., et al. (2014). A phase 1 study evaluating the safety and tolerability of otlertuzumab, an anti-CD37 mono-specific ADAPTIR therapeutic protein in chronic lymphocytic leukemia. Blood 123, 1302-1308. doi: 10.1182/blood-2013-07-512137
16. Carmo, A. M., and Wright, M. D. (1995). Association of the transmembrane 4 superfamily molecule CD53 with a tyrosine phosphatase activity. Eur. J. Immunol . 25, 2090-2095. doi: 10.1002/eji.1830250743
17. Charrin, S., Le Naour, F., Labas, V., Billard, M., Le Caer, J. P., Emile, J. F., et al. (2003). EWI-2 is a new component of the tetraspanin web in hepatocytes and lymphoid cells. Biochem. J . 373, 409-421. doi: 10.1042/BJ20030343
18. Charrin, S., Le Naour, F., Oualid, M., Billard, M., Faure, G., Hanash, S. M., et al. (2001). The major CD9 and CD81 molecular partner. Identification and characterization of the complexes. J. Biol. Chem . 276, 14329-14337. doi: 10.1074/jbc.M011297200
19. Charrin, S., Le Naour, F., Silvie, O., Milhiet, P. E., Boucheix, C., and Rubinstein, E. (2009). Lateral organization of membrane proteins: tetraspanins spin their web. Biochem. J . 420, 133-154. doi: 10.1042/BJ20082422
20. Charrin, S., Manie, S., Oualid, M., Billard, M., Boucheix, C., and Rubinstein, E. (2002). Differential stability of tetraspanin/tetraspanin interactions: role of palmitoylation. FEBS Lett . 516, 139-144. doi: 10.1016/S0014-5793(02)02522-X
21. Chen, Z., Pasquini, M., Hong, B., Dehart, S., Heikens, M., and Tsai, S. (2005). The human Penumbra gene is mapped to a region on chromosome 7 frequently deleted in myeloid malignancies. Cancer Genet. Cytogenet . 162, 95-98. doi: 10.1016/j.cancergencyto.2005.03.017
22. Claas, C., Stipp, C. S., and Hemler, M. E. (2001). Evaluation of prototype transmembrane 4 superfamily protein complexes and their relation to lipid rafts. J. Biol. Chem . 276, 7974-7984. doi: 10.1074/jbc.M008650200
23. Clark, K. L., Oelke, A., Johnson, M. E., Eilert, K. D., Simpson, P. C., and Todd, S. C. (2004). CD81 associates with 14-3-3 in a redox-regulated palmitoylation-dependent manner. J. Biol. Chem . 279, 19401-19406. doi: 10.1074/jbc.M312626200
24. Dahle, J., Repetto-Llamazares, A. H., Mollatt, C. S., Melhus, K. B., Bruland, O. S., Kolstad, A., et al. (2013). Evaluating antigen targeting and anti-tumor activity of a new anti-CD37 radioimmunoconjugate against non-Hodgkin's lymphoma. Anticancer Res . 33, 85-95.
25. De Bruyne, E., Bos, T. J., Asosingh, K., Vande Broek, I., Menu, E., Van Valckenborgh, E., et al. (2008). Epigenetic silencing of the tetraspanin CD9 during disease progression in multiple myeloma cells and correlation with survival. Clin. Cancer Res . 14, 2918-2926. doi: 10.1158/1078-0432.CCR-07-4489
26. Deckert, J., Park, P. U., Chicklas, S., Yi, Y., Li, M., Lai, K. C., et al. (2013). A novel anti-CD37 antibody-drug conjugate with multiple anti-tumor mechanisms for the treatment of B-cell malignancies. Blood 122, 3500-3510. doi: 10.1182/blood-2013-05-505685
27. Deckert, J., Ponte, J. F., Coccia, J. A., Lanieri, L., Chicklas, S., Yi, Y., et al. (2014). "Preclinical mechanistic studies investigating neutrophil and lymphoid cell depletion by IMGN529, a CD37-targeting antibody-drug conjugate (ADC)," in Abstract #3119, 56th Annual Meeting of the American Society of Hematology (San Francisco, CA).
28. Gartlan, K. H., Belz, G. T., Tarrant, J. M., Minigo, G., Katsara, M., Sheng, K. C., et al. (2010). A complementary role for the tetraspanins CD37 and Tssc6 in cellular immunity. J. Immunol . 185, 3158-3166. doi: 10.4049/jimmunol.0902867
29. Gartlan, K. H., Wee, J. L., Demaria, M. C., Nastovska, R., Chang, T. M., Jones, E. L., et al. (2013). Tetraspanin CD37 contributes to the initiation of cellular immunity by promoting dendritic cell migration. Eur. J. Immunol . 43, 1208-1219. doi: 10.1002/eji.201242730
30. Gopal, A. K., Tarantolo, S. R., Bellam, N., Green, D. J., Griffin, M., Feldman, T., et al. (2014). Phase 1b study of otlertuzumab (TRU-016), an anti-CD37 monospecific ADAPTIR therapeutic protein, in combination with rituximab and bendamustine in relapsed indolent lymphoma patients. Invest. New Drugs 32, 1213-1225. doi: 10.1007/s10637-014-0125-2
31. Goschnick, M. W., Lau, L. M., Wee, J. L., Liu, Y. S., Hogarth, P. M., Robb, L. M., et al. (2006). Impaired "outside-in" integrin alphaIIbbeta3 signaling and thrombus stability in TSSC6-deficient mice. Blood 108, 1911-1918. doi: 10.1182/blood-2006-02-004267
32. Gutierrez-Lopez, M. D., Ovalle, S., Yanez-Mo, M., Sanchez-Sanchez, N., Rubinstein, E., Olmo, N., et al. (2003). A functionally relevant conformational epitope on the CD9 tetraspanin depends on the association with activated beta1 integrin. J. Biol. Chem . 278, 208-218. doi: 10.1074/jbc.M207805200
33. Haining, E. J., Yang, J., Bailey, R. L., Khan, K., Collier, R., Tsai, S., et al. (2012). The TspanC8 subgroup of tetraspanins interacts with A disintegrin and metalloprotease 10 (ADAM10) and regulates its maturation and cell surface expression. J. Biol. Chem . 287, 39753-39765. doi: 10.1074/jbc.M112.416503
34. Heider, K. H., Kiefer, K., Zenz, T., Volden, M., Stilgenbauer, S., Ostermann, E., et al. (2011). A novel Fc-engineered monoclonal antibody to CD37 with enhanced ADCC and high proapoptotic activity for treatment of B-cell malignancies. Blood 118, 4159-4168. doi: 10.1182/blood-2011-04-351932
35. Heikens, M. J., Cao, T. M., Morita, C., Dehart, S. L., and Tsai, S. (2007). Penumbra encodes a novel tetraspanin that is highly expressed in erythroid progenitors and promotes effective erythropoiesis. Blood 109, 3244-3252. doi: 10.1182/blood-2006-09-046672
36. Hemler, M. E. (2005). Tetraspanin functions and associated microdomains. Nat. Rev. Mol. Cell Biol . 6, 801-811. doi: 10.1038/nrm1736
37. Hemler, M. E. (2014). Tetraspanin proteins promote multiple cancer stages. Nat. Rev. Cancer 14, 49-60. doi: 10.1038/nrc3640
38. Horváth, G., Serru, V., Clay, D., Billard, M., Boucheix, C., and Rubinstein, E. (1998). CD19 Is Linked to the Integrin-associated Tetraspans CD9, CD81, and CD82. J. Biol. Chem . 273, 30537-30543. doi: 10.1074/jbc.273.46.30537
39. Hu, X., Xuan, H., Du, H., Jiang, H., and Huang, J. (2014). Down-regulation of CD9 by methylation decreased bortezomib sensitivity in multiple myeloma. PLoS ONE 9:e95765. doi: 10.1371/journal.pone.0095765
40. Huhn, D., Von Schilling, C., Wilhelm, M., Ho, A. D., Hallek, M., Kuse, R., et al. (2001). Rituximab therapy of patients with B-cell chronic lymphocytic leukemia. Blood 98, 1326-1331. doi: 10.1182/blood.V98.5.1326
41. Imai, T., Mayumi, K., Nishimura, M., and Yoshie, O. (1995). Molecular analyses of the association of CD4 with two members of the transmembrane 4 superfamily, CD81 and CD82. J. Immunol . 155, 1229-1239.
42. Keating, M. J., O'Brien, S., Albitar, M., Lerner, S., Plunkett, W., Giles, F., et al. (2005). Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia. J. Clin. Oncol . 23, 4079-4088. doi: 10.1200/JCO.2005.12.051
43. Kitadokoro, K., Bordo, D., Galli, G., Petracca, R., Falugi, F., Abrignani, S., et al. (2001). CD81 extracellular domain 3D structure: insight into the tetraspanin superfamily structural motifs. EMBO J . 20, 12-18. doi: 10.1093/emboj/20.1.12
44. Knobeloch, K. P., Wright, M. D., Ochsenbein, A. F., Liesenfeld, O., Lohler, J., Zinkernagel, R. M., et al. (2000). Targeted inactivation of the tetraspanin CD37 impairs T-cell-dependent B-cell response under suboptimal costimulatory conditions. Mol. Cell. Biol . 20, 5363-5369. doi: 10.1128/MCB.20.15.5363-5369.2000
45. Kolstad, A., Madsbu, U., Dahle, J., Stokke, C., Bach-Gansmo, T., Løndalen, A. M., et al. (2014). "A phase i study of 177 lu-DOTA-HH1 (Betalutin) radioimmunotherapy for patients with relapsed CD37+ Non-Hodgkin's B cell lymphoma," in Abstract #3094, 56th Annual Meeting of the American Society of Hematology (San Francisco, CA).
46. Krause, G., Patz, M., Isaeva, P., Wigger, M., Baki, I., Vondey, V., et al. (2012). Action of novel CD37 antibodies on chronic lymphocytic leukemia cells. Leukemia 26, 546-549. doi: 10.1038/leu.2011.233
47. Lapalombella, R., Yeh, Y. Y., Wang, L., Ramanunni, A., Rafiq, S., Jha, S., et al. (2012). Tetraspanin CD37 directly mediates transduction of survival and apoptotic signals. Cancer Cell 21, 694-708. doi: 10.1016/j.ccr.2012.03.040
48. Lazar, G. A., Dang, W., Karki, S., Vafa, O., Peng, J. S., Hyun, L., et al. (2006). Engineered antibody Fc variants with enhanced effector function. Proc. Natl. Acad. Sci. U.S.A . 103, 4005-4010. doi: 10.1073/pnas.0508123103
49. Le Naour, F., Andre, M., Boucheix, C., and Rubinstein, E. (2006a). Membrane microdomains and proteomics: lessons from tetraspanin microdomains and comparison with lipid rafts. Proteomics 6, 6447-6454. doi: 10.1002/pmic.200600282
50. Le Naour, F., Andre, M., Greco, C., Billard, M., Sordat, B., Emile, J. F., et al. (2006b). Profiling of the tetraspanin web of human colon cancer cells. Mol. Cell. Proteomics 5, 845-857. doi: 10.1074/mcp.M500330-MCP200
51. Leung, K. T., Chan, K. Y., Ng, P. C., Lau, T. K., Chiu, W. M., Tsang, K. S., et al. (2011). The tetraspanin CD9 regulates migration, adhesion, and homing of human cord blood CD34+ hematopoietic stem and progenitor cells. Blood 117, 1840-1850. doi: 10.1182/blood-2010-04-281329
52. Levy, S. (2014). Function of the tetraspanin molecule CD81 in B and T cells. Immunol. Res . 58, 179-185. doi: 10.1007/s12026-014-8490-7
53. Levy, S., Todd, S. C., and Maecker, H. T. (1998). CD81 (TAPA-1): a molecule involved in signal transduction and cell adhesion in the immune system. Annu. Rev. Immunol . 16, 89-109. doi: 10.1146/annurev.immunol.16.1.89
54. Link, M. P., Bindl, J., Meeker, T. C., Carswell, C., Doss, C. A., Warnke, R. A., et al. (1986). A unique antigen on mature B cells defined by a monoclonal antibody. J. Immunol . 137, 3013-3018.
55. Little, K. D., Hemler, M. E., and Stipp, C. S. (2004). Dynamic regulation of a GPCR-tetraspanin-G protein complex on intact cells: central role of CD81 in facilitating GPR56-Galpha q/11 association. Mol. Biol. Cell 15, 2375-2387. doi: 10.1091/mbc.E03-12-0886
56. Luu, V. P., Hevezi, P., Vences-Catalan, F., Maravillas-Montero, J. L., White, C. A., Casali, P., et al. (2013). TSPAN33 is a novel marker of activated and malignant B cells. Clin. Immunol . 149, 388-399. doi: 10.1016/j.clim.2013.08.005
57. Maecker, H. T., and Levy, S. (1997). Normal lymphocyte development but delayed humoral immune response in CD81-null mice. J. Exp. Med . 185, 1505-1510. doi: 10.1084/jem.185.8.1505
58. Maecker, H. T., Todd, S. C., and Levy, S. (1997). The tetraspanin superfamily: molecular facilitators. FASEB J . 11, 428-442.
59. Mannion, B. A., Berditchevski, F., Kraeft, S., Chen, L. B., and Hemler, M. E. (1996). Transmembrane-4 Superfamily Proteins CD81 (TAPA-1), CD82, CD63, and CD53 Specifically Associate with lntegrin α4Β1 (CD49d/CD29). J. Immunol . 157, 2039-2047.
60. Masellis-Smith, A., and Shaw, A. R. (1994). CD9-regulated adhesion. Anti-CD9 monoclonal antibody induce pre-B cell adhesion to bone marrow fibroblasts through de novo recognition of fibronectin. J. Immunol . 152, 2768-2777.
61. Mattila, P. K., Feest, C., Depoil, D., Treanor, B., Montaner, B., Otipoby, K. L., et al. (2013). The actin and tetraspanin networks organize receptor nanoclusters to regulate B cell receptor-mediated signaling. Immunity 38, 461-474. doi: 10.1016/j.immuni.2012.11.019
62. Meyer-Wentrup, F., Figdor, C. G., Ansems, M., Brossart, P., Wright, M. D., Adema, G. J., et al. (2007). Dectin-1 interaction with tetraspanin CD37 inhibits IL-6 production. J. Immunol . 178, 154-162. doi: 10.4049/jimmunol.178.1.154
63. Min, G., Wang, H., Sun, T. T., and Kong, X. P. (2006). Structural basis for tetraspanin functions as revealed by the cryo-EM structure of uroplakin complexes at 6-A resolution. J. Cell Biol . 173, 975-983. doi: 10.1083/jcb.200602086
64. Mollinedo, F., Fontan, G., Barasoain, I., and Lazo, P. A. (1997). Recurrent infectious diseases in human CD53 deficiency. Clin. Diagn. Lab. Immunol . 4, 229-231.
65. Mollinedo, F., Martin-Martin, B., Gajate, C., and Lazo, P. A. (1998). Physiological activation of human neutrophils down-regulates CD53 cell surface antigen. J. Leukoc. Biol . 63, 699-706.
66. Nakamoto, T., Murayama, Y., Oritani, K., Boucheix, C., Rubinstein, E., Nishida, M., et al. (2009). A novel therapeutic strategy with anti-CD9 antibody in gastric cancers. J. Gastroenterol . 44, 889-896. doi: 10.1007/s00535-009-0081-3
67. Nicholson, R. H., Pantano, S., Eliason, J. F., Galy, A., Weiler, S., Kaplan, J., et al. (2000). Phemx, a novel mouse gene expressed in hematopoietic cells maps to the imprinted cluster on distal chromosome 7. Genomics 68, 13-21. doi: 10.1006/geno.2000.6277
68. Olweus, J., Lund-Johansen, F., and Horejsi, V. (1993). CD53, a protein with four membrane-spanning domains, mediates signal transduction in human monocytes and B cells. J. Immunol . 151, 707-716.
69. Ono, M., Handa, K., Withers, D. A., and Hakomori, S. (1999). Motility inhibition and apoptosis are induced by metastasis-suppressing gene product CD82 and its analogue CD9, with concurrent glycosylation. Cancer Res . 59, 2335-2339.
70. Ono, M., Handa, K., Withers, D. A., and Hakomori, S. (2000). Glycosylation effect on membrane domain (GEM) involved in cell adhesion and motility: a preliminary note on functional alpha3, alpha5-CD82 glycosylation complex in ldlD 14 cells. Biochem. Biophys. Res. Commun . 279, 744-750. doi: 10.1006/bbrc.2000.4030
71. Pagel, J. M., Spurgeon, S. E., Byrd, J. C., Awan, F. T., Flinn, I. W., Lanasa, M. C., et al. (2015). Otlertuzumab (TRU-016), an anti-CD37 monospecific ADAPTIR therapeutic protein, for relapsed or refractory NHL patients. Br. J. Haematol . 168, 38-45. doi: 10.1111/bjh.13099
72. Pileri, P., Uematsu, Y., Campagnoli, S., Galli, G., Falugi, F., Petracca, R., et al. (1998). Binding of hepatitis C virus to CD81. Science 282, 938-941. doi: 10.1126/science.282.5390.938
73. Press, O. W., Eary, J. F., Badger, C. C., Martin, P. J., Appelbaum, F. R., Levy, R., et al. (1989). Treatment of refractory non-Hodgkin's lymphoma with radiolabeled MB-1 (anti-CD37) antibody. J. Clin. Oncol . 7, 1027-1038.
74. Press, O. W., Howell-Clark, J., Anderson, S., and Bernstein, I. (1994). Retention of B-cell-specific monoclonal antibodies by human lymphoma cells. Blood 83, 1390-1397.
75. Qi, J. C., Wang, J., Mandadi, S., Tanaka, K., Roufogalis, B. D., Madigan, M. C., et al. (2006). Human and mouse mast cells use the tetraspanin CD9 as an alternate interleukin-16 receptor. Blood 107, 135-142. doi: 10.1182/blood-2005-03-1312
76. Rafiq, S., Siadak, A., Butchar, J. P., Cheney, C., Lozanski, G., Jacob, N. K., et al. (2013). Glycovariant anti-CD37 monospecific protein therapeutic exhibits enhanced effector cell-mediated cytotoxicity against chronic and acute B cell malignancies. MAbs 5, 723-735. doi: 10.4161/mabs.25282
77. Repetto-Llamazares, A. H., Larsen, R. H., Giusti, A. M., Riccardi, E., Bruland, O. S., Selbo, P. K., et al. (2014). 177Lu-DOTA-HH1, a novel anti-CD37 radio-immunoconjugate: a study of toxicity in nude mice. PLoS ONE 9:e103070. doi: 10.1371/journal.pone.0103070
78. Robak, T., Hellman, A., Kloczko, J., Loscertales, J., Lech-Maranda, E. J., Pagel, J. M., et al. (2013). "Phase 2 study of otlertuzumab (TRU-016), an anti-CD37 ADAPTIRTM protein, in combination with bendamustine vs bendamustine alone in patients with relapsed chronic lymphocytic leukemia (CLL)," in Abstract #2860, 55th Annual Meeting of the American Society of Hematology (New Orleans, LA).
79. Robb, L., Tarrant, J., Groom, J., Ibrahim, M., Li, R., Borobakas, B., et al. (2001). Molecular characterisation of mouse and human TSSC6: evidence that TSSC6 is a genuine member of the tetraspanin superfamily and is expressed specifically in haematopoietic organs. Biochim. Biophys. Acta 1522, 31-41. doi: 10.1016/S0167-4781(01)00306-2
80. Romanska, H. M., and Berditchevski, F. (2011). Tetraspanins in human epithelial malignancies. J. Pathol . 223, 4-14. doi: 10.1002/path.2779
81. Schwartz-Albiez, R., Dorken, B., Hofmann, W., and Moldenhauer, G. (1988). The B cell-associated CD37 antigen (gp40-52). Structure and subcellular expression of an extensively glycosylated glycoprotein. J. Immunol . 140, 905-914.
82. Scott, A. M., Wolchok, J. D., and Old, L. J. (2012). Antibody therapy of cancer. Nat. Rev. Cancer 12, 278-287. doi: 10.1038/nrc3236
83. Seita, J., Sahoo, D., Rossi, D. J., Bhattacharya, D., Serwold, T., Inlay, M. A., et al. (2012). Gene Expression Commons: an open platform for absolute gene expression profiling. PLoS ONE 7:e40321. doi: 10.1371/journal.pone.0040321
84. Shallal, S., and Kornbluth, J. (2000). CD9 expression enhances the susceptibility of myeloma cell lines to cell-mediated cytolysis. Blood 96, 224-233.
85. Sheng, K. C., Van Spriel, A. B., Gartlan, K. H., Sofi, M., Apostolopoulos, V., Ashman, L., et al. (2009). Tetraspanins CD37 and CD151 differentially regulate Ag presentation and T-cell co-stimulation by DC. Eur. J. Immunol . 39, 50-55. doi: 10.1002/eji.200838798
86. Shinkawa, T., Nakamura, K., Yamane, N., Shoji-Hosaka, E., Kanda, Y., Sakurada, M., et al. (2003). The absence of fucose but not the presence of galactose or bisecting N-acetylglucosamine of human IgG1 complex-type oligosaccharides shows the critical role of enhancing antibody-dependent cellular cytotoxicity. J. Biol. Chem . 278, 3466-3473. doi: 10.1074/jbc.M210665200
87. Shoham, T., Rajapaksa, R., Kuo, C. C., Haimovich, J., and Levy, S. (2006). Building of the tetraspanin web: distinct structural domains of CD81 function in different cellular compartments. Mol. Cell. Biol . 26, 1373-1385. doi: 10.1128/MCB.26.4.1373-1385.2006
88. Stathis, A., Freedman, A. S., Flinn, I. W., Maddocks, K. J., Weitman, S., Berdeja, J. G., et al. (2014). "A Phase I study of IMGN529, an antibody-drug conjugate (ADC) targeting CD37, in adult patients with relapsed or refractory b-cell non-hodgkin's lymphoma (NHL)," in Abstract #1760, 56th Annual Meeting of the American Society of Hematology (San Francisco, CA).
89. Suzuki, T., Coustan-Smith, E., Mihara, K., and Campana, D. (2002). Signals mediated by FcgammaRIIA suppress the growth of B-lineage acute lymphoblastic leukemia cells. Leukemia 16, 1276-1284. doi: 10.1038/sj.leu.2402523
90. Szöllósi, J., Horejsí, V., Bene, L., Angelisová, P., and Damjanovich, S. (1996). Supramolecular complexes of MHC class I, MHC class II, CD20, and tetraspan molecules (CD53, CD81, and CD82) at the surface of a B cell line JY. J. Immunol . 157, 2939-2946.
91. Tai, X. G., Yashiro, Y., Abe, R., Toyooka, K., Wood, C. R., Morris, J., et al. (1996). A role for CD9 molecules in T cell activation. J. Exp. Med . 184, 753-758. doi: 10.1084/jem.184.2.753
92. Tarrant, J. M., Groom, J., Metcalf, D., Li, R., Borobokas, B., Wright, M. D., et al. (2002). The absence of Tssc6, a member of the tetraspanin superfamily, does not affect lymphoid development but enhances in vitro T-cell proliferative responses. Mol. Cell. Biol . 22, 5006-5018. doi: 10.1128/MCB.22.14.5006-5018.2002
93. Tarrant, J. M., Robb, L., Van Spriel, A. B., and Wright, M. D. (2003). Tetraspanins: molecular organisers of the leukocyte surface. Trends Immunol . 24, 610-617. doi: 10.1016/j.it.2003.09.011
94. Van Spriel, A. B., De Keijzer, S., Van Der Schaaf, A., Gartlan, K. H., Sofi, M., Light, A., et al. (2012). The tetraspanin CD37 orchestrates the alpha(4)beta(1) integrin-Akt signaling axis and supports long-lived plasma cell survival. Sci. Signal 5, ra82. doi: 10.1126/scisignal.2003113
95. Van Spriel, A. B., Puls, K. L., Sofi, M., Pouniotis, D., Hochrein, H., Orinska, Z., et al. (2004). A regulatory role for CD37 in T cell proliferation. J. Immunol . 172, 2953-2961. doi: 10.4049/jimmunol.172.5.2953
96. Van Spriel, A. B., Sofi, M., Gartlan, K. H., Van Der Schaaf, A., Verschueren, I., Torensma, R., et al. (2009). The tetraspanin protein CD37 regulates IgA responses and anti-fungal immunity. PLoS Pathog . 5:e1000338. doi: 10.1371/journal.ppat.1000338
97. Veenbergen, S., and Van Spriel, A. B. (2011). Tetraspanins in the immune response against cancer. Immunol. Lett . 138, 129-136. doi: 10.1016/j.imlet.2011.03.010
98. Voehringer, D. W., Hirschberg, D. L., Xiao, J., Lu, Q., Roederer, M., Lock, C. B., et al. (2000). Gene microarray identification of redox and mitochondrial elements that control resistance or sensitivity to apoptosis. Proc. Natl. Acad. Sci. U.S.A . 97, 2680-2685. doi: 10.1073/pnas.97.6.2680
99. Waterhouse, R., Ha, C., and Dveksler, G. S. (2002). Murine CD9 is the receptor for pregnancy-specific glycoprotein 17. J. Exp. Med . 195, 277-282. doi: 10.1084/jem.20011741
100. White, A., Lamb, P. W., and Barrett, J. C. (1998). Frequent downregulation of the KAI1(CD82) metastasis suppressor protein in human cancer cell lines. Oncogene 16, 3143-3149. doi: 10.1038/sj.onc.1201852
101. Witherden, D. A., Boismenu, R., and Havran, W. L. (2000). CD81 and CD28 costimulate T cells through distinct pathways. J. Immunol . 165, 1902-1909. doi: 10.4049/jimmunol.165.4.1902
102. Worthington, R. E., Carroll, R. C., and Boucheix, C. (1990). Platelet activation by CD9 monoclonal antibodies is mediated by the Fc gamma II receptor. Br. J. Haematol . 74, 216-222. doi: 10.1111/j.1365-2141.1990.tb02568.x
103. Wright, M. D., Geary, S. M., Fitter, S., Moseley, G. W., Lau, L. M., Sheng, K. C., et al. (2004). Characterization of mice lacking the tetraspanin superfamily member CD151. Mol. Cell. Biol . 24, 5978-5988. doi: 10.1128/MCB.24.13.5978-5988.2004
104. Yang, X., Claas, C., Kraeft, S. K., Chen, L. B., Wang, Z., Kreidberg, J. A., et al. (2002). Palmitoylation of tetraspanin proteins: modulation of CD151 lateral interactions, subcellular distribution, and integrin-dependent cell morphology. Mol. Biol. Cell 13, 767-781. doi: 10.1091/mbc.01-05-0275
105. Yang, X., Kovalenko, O. V., Tang, W., Claas, C., Stipp, C. S., and Hemler, M. E. (2004). Palmitoylation supports assembly and function of integrin-tetraspanin complexes. J. Cell Biol . 167, 1231-1240. doi: 10.1083/jcb.200404100
106. Yauch, R. L., Berditchevski, F., Harler, M. B., Reichner, J., and Hemler, M. E. (1998). Highly stoichiometric, stable, and specific association of integrin alpha3beta1 with CD151 provides a major link to phosphatidylinositol 4-kinase, and may regulate cell migration. Mol. Biol. Cell 9, 2751-2765. doi: 10.1091/mbc.9.10.2751
107. Yauch, R. L., Kazarov, A. R., Desai, B., Lee, R. T., and Hemler, M. E. (2000). Direct extracellular contact between integrin alpha(3)beta(1) and TM4SF protein CD151. J. Biol. Chem . 275, 9230-9238. doi: 10.1074/jbc.275.13.9230
108. Yu, B., Mao, Y., Yuan, Y., Yue, C., Wang, X., Mo, X., et al. (2013). Targeted drug delivery and cross-linking induced apoptosis with anti-CD37 based dual-ligand immunoliposomes in B chronic lymphocytic leukemia cells. Biomaterials 34, 6185-6193. doi: 10.1016/j.biomaterials.2013.04.063
109. Yunta, M., and Lazo, P. A. (2003). Apoptosis protection and survival signal by the CD53 tetraspanin antigen. Oncogene 22, 1219-1224. doi: 10.1038/sj.onc.1206183
110. Zevian, S., Winterwood, N. E., and Stipp, C. S. (2011). Structure-function analysis of tetraspanin CD151 reveals distinct requirements for tumor cell behaviors mediated by alpha3beta1 versus alpha6beta4 integrin. J. Biol. Chem . 286, 7496-7506. doi: 10.1074/jbc.M110.173583
111. Zhang, X. A., Bontrager, A. L., and Hemler, M. E. (2001). Transmembrane-4 superfamily proteins associate with activated protein kinase C (PKC) and link PKC to specific beta(1) integrins. J. Biol. Chem . 276, 25005-25013. doi: 10.1074/jbc.M102156200
112. Zhao, X., Lapalombella, R., Joshi, T., Cheney, C., Gowda, A., Hayden-Ledbetter, M. S., et al. (2007). Targeting CD37-positive lymphoid malignancies with a novel engineered small modular immunopharmaceutical. Blood 110, 2569-2577. doi: 10.1182/blood-2006-12-062927
113. Zijlstra, A., Lewis, J., Degryse, B., Stuhlmann, H., and Quigley, J. P. (2008). The inhibition of tumor cell intravasation and subsequent metastasis via regulation of in vivo tumor cell motility by the tetraspanin CD151. Cancer Cell 13, 221-234. doi: 10.1016/j.ccr.2008.01.031
114. Zoller, M. (2009). Tetraspanins: push and pull in suppressing and promoting metastasis. Nat. Rev. Cancer 9, 40-55. doi: 10.1038/nrc2543
115. Zuidscherwoude, M., De Winde, C. M., Cambi, A., and Van Spriel, A. B. (2014). Microdomains in the membrane landscape shape antigen-presenting cell function. J. Leukoc. Biol . 95, 251-263. doi: 10.1189/jlb.0813440